166 related articles for article (PubMed ID: 24530566)
1. Effective protocol for the investigation of physicochemical and conformational stability and aggregation kinetics measurements of therapeutic IgG2 monoclonal antibody.
Aboel Dahab A; El-Hag D
J Immunol Methods; 2014 Mar; 405():154-66. PubMed ID: 24530566
[TBL] [Abstract][Full Text] [Related]
2. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements.
Cheng W; Joshi SB; He F; Brems DN; He B; Kerwin BA; Volkin DB; Middaugh CR
J Pharm Sci; 2012 May; 101(5):1701-20. PubMed ID: 22323186
[TBL] [Abstract][Full Text] [Related]
3. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
[TBL] [Abstract][Full Text] [Related]
4. Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies.
Ejima D; Tsumoto K; Fukada H; Yumioka R; Nagase K; Arakawa T; Philo JS
Proteins; 2007 Mar; 66(4):954-62. PubMed ID: 17154421
[TBL] [Abstract][Full Text] [Related]
5. Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodies.
Thakkar SV; Sahni N; Joshi SB; Kerwin BA; He F; Volkin DB; Middaugh CR
Protein Sci; 2013 Oct; 22(10):1295-305. PubMed ID: 23893936
[TBL] [Abstract][Full Text] [Related]
6. Conformational and Colloidal Stabilities of Isolated Constant Domains of Human Immunoglobulin G and Their Impact on Antibody Aggregation under Acidic Conditions.
Yageta S; Lauer TM; Trout BL; Honda S
Mol Pharm; 2015 May; 12(5):1443-55. PubMed ID: 25871775
[TBL] [Abstract][Full Text] [Related]
7. Conformational implications of an inversed pH-dependent antibody aggregation.
Perico N; Purtell J; Dillon TM; Ricci MS
J Pharm Sci; 2009 Sep; 98(9):3031-42. PubMed ID: 18803243
[TBL] [Abstract][Full Text] [Related]
8. Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics.
Rao G; Iyer V; Kosloski MP; Pisal DS; Shin E; Middaugh CR; Balu-Iyer SV
J Pharm Sci; 2010 Apr; 99(4):1697-706. PubMed ID: 19798762
[TBL] [Abstract][Full Text] [Related]
9. The effect of solvent environment on the conformation and stability of human polyclonal IgG in solution.
Szenczi A; Kardos J; Medgyesi GA; Závodszky P
Biologicals; 2006 Mar; 34(1):5-14. PubMed ID: 16168667
[TBL] [Abstract][Full Text] [Related]
10. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.
Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD
MAbs; 2015; 7(1):84-95. PubMed ID: 25524268
[TBL] [Abstract][Full Text] [Related]
11. Role of cosolutes in the aggregation kinetics of monoclonal antibodies.
Nicoud L; Sozo M; Arosio P; Yates A; Norrant E; Morbidelli M
J Phys Chem B; 2014 Oct; 118(41):11921-30. PubMed ID: 25243487
[TBL] [Abstract][Full Text] [Related]
12. High Throughput Prediction Approach for Monoclonal Antibody Aggregation at High Concentration.
Zidar M; Šušterič A; Ravnik M; Kuzman D
Pharm Res; 2017 Sep; 34(9):1831-1839. PubMed ID: 28593474
[TBL] [Abstract][Full Text] [Related]
13. Nonnative aggregation of an IgG1 antibody in acidic conditions: part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates.
Brummitt RK; Nesta DP; Chang L; Chase SF; Laue TM; Roberts CJ
J Pharm Sci; 2011 Jun; 100(6):2087-103. PubMed ID: 21213308
[TBL] [Abstract][Full Text] [Related]
14. Circular dichroism spectroscopy as a tool for monitoring aggregation in monoclonal antibody therapeutics.
Joshi V; Shivach T; Yadav N; Rathore AS
Anal Chem; 2014 Dec; 86(23):11606-13. PubMed ID: 25350583
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies.
Sahin E; Grillo AO; Perkins MD; Roberts CJ
J Pharm Sci; 2010 Dec; 99(12):4830-48. PubMed ID: 20821389
[TBL] [Abstract][Full Text] [Related]
16. Protein structural conformation and not second virial coefficient relates to long-term irreversible aggregation of a monoclonal antibody and ovalbumin in solution.
Bajaj H; Sharma VK; Badkar A; Zeng D; Nema S; Kalonia DS
Pharm Res; 2006 Jun; 23(6):1382-94. PubMed ID: 16715374
[TBL] [Abstract][Full Text] [Related]
17. Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability.
Harn N; Allan C; Oliver C; Middaugh CR
J Pharm Sci; 2007 Mar; 96(3):532-46. PubMed ID: 17083094
[TBL] [Abstract][Full Text] [Related]
18. On the role of salt type and concentration on the stability behavior of a monoclonal antibody solution.
Arosio P; Jaquet B; Wu H; Morbidelli M
Biophys Chem; 2012 Jul; 168-169():19-27. PubMed ID: 22750560
[TBL] [Abstract][Full Text] [Related]
19. Relation of Colloidal and Conformational Stabilities to Aggregate Formation in a Monoclonal Antibody.
Oyama H; Koga H; Tadokoro T; Maenaka K; Shiota A; Yokoyama M; Noda M; Torisu T; Uchiyama S
J Pharm Sci; 2020 Jan; 109(1):308-315. PubMed ID: 31669120
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal Antibodies Follow Distinct Aggregation Pathways During Production-Relevant Acidic Incubation and Neutralization.
Skamris T; Tian X; Thorolfsson M; Karkov HS; Rasmussen HB; Langkilde AE; Vestergaard B
Pharm Res; 2016 Mar; 33(3):716-28. PubMed ID: 26563206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
